Novavax, Inc.

NASDAQ:NVAX

Biotechnology

Healthcare
$7.96 -1.84%

-$0.18 today

Market cap
$1.31B
Beta
2.41
P/E (TTM)
-17.3
EPS (TTM)
-$0.54
52W Low $6.13High $11.97

Volume 4.24M

Average 4.58M

NVAX Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Novavax, Inc.NASDAQ: NVAX

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income turns negative

Q1 FY2026 net income was -$9.49M, compared with $518.65M a year earlier. Trailing-twelve-month net income was -$87.84M.

Context

  • Net income amounted to 39.2% of revenue in FY2025, up 11.7 pp from a year earlier.
  • Net income increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 5 analysts of -$12.8M (-102.9%) for the fiscal year ending Dec 2026, a slowdown from the +334.8% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$9.49M-154.2% QoQ
Last fiscal yearDec 2025
$440.3M+334.8% YoY
LTMMar 2026
-$87.84M-118.3% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-101.8%-158.8%-57.0 pp
1 year+334.8%-102.9%-437.7 pp
3-year CAGR———
5-year CAGR-15.2%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
440.3M USD
Year-over-year change
+334.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How NVAX compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -118.3% is the lowest of 8, against a peer median of +15.4%.
  • Net income amounts to 14.7% of revenue for NVAX, versus a peer median of 93.5%.
NVAX Competitors
Net Income for NVAX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRNAModerna, Inc.LTM Sep 2026$2.79B USD-10.5%—110.5%
BNTXBioNTech SELTM Jun 2026€1.71B EUR+348.2%—64.7%
PCVXVaxcyte, Inc.LTM Jun 2026$1.38B USD+152.9%+50.8%—
VALNValneva SELTM Mar 2026€146.23M EUR+81.9%-7.0%93.5%
NVAXNovavax, Inc.LTM Mar 2026$87.84M USD-118.3%—14.7%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$84.93M USD-12.0%-32.8%—
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$78.67M USD+15.4%—173.5%
EBSEmergent BioSolutions Inc.LTM Mar 2026$8.6M USD-93.5%—1.3%
Peer median (excluding NVAX) —+15.4%-7.0%93.5%

Competitors are the stored peer set for NVAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(1.74B)(657.94M)(545.06M)(187.5M)440.3M
Depreciation & Amortization12.66M29.05M41.23M48.5M27.61M
Deferred Income Tax00000
Stock-Based Compensation183.63M130.3M85.36M48.15M36.02M
Change in Working Capital1.73B(361.15M)(376.84M)48.48M(887.71M)
Accounts Receivables(192.27M)249.17M(274.44M)354.09M61.04M
Inventory(600.33M)(477.8M)(74.46M)12.91M(3.24M)
Accounts Payables600.33M913.4M(378.81M)(385.63M)(322.57M)
Other Working Capital1.93B(1.05B)350.87M67.11M(622.94M)
Other Non-Cash Items136.79M443.8M81.35M(44.89M)139.14M
Operating Cash Flow322.95M(415.94M)(713.97M)(87.26M)(244.64M)
Capital Expenditures(57.49M)(92.99M)(58.81M)(13.06M)(5.56M)
Acquisitions (Net)57.49M00192.64M0
Purchases of Investments(2.17M)00(825.59M)(445.27M)
Sales of Investments159.81M00443.55M353.74M
Other Investing Activities(57.49M)00018.83M
Investing Cash Flow100.15M(92.99M)(58.81M)(204.04M)(78.27M)
Debt Repayment(127.91M)81.66M(352.35M)(3.99M)32.53M
Common Stock Issued564.86M249.23M360.24M263.27M0
Common Stock Repurchased0000(4.8M)
Dividends Paid00000
Other Financing Activities24.76M(5.9M)(3.59M)1.31M0
Financing Cash Flow461.71M324.99M4.47M260.58M27.74M
Effect of Forex Changes(5.29M)4.52M3.27M(7.8M)5.93M
Net Change in Cash879.52M(179.41M)(765.04M)(38.52M)(289.24M)
Free Cash Flow265.46M(508.92M)(772.77M)(100.32M)(250.2M)

Novavax, Inc.

NASDAQ:NVAX

Intrinsic Alpha fair value

Locked

Current Price

$7.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.